Cargando…

Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer

PI3Kα-selective inhibitor BYL719 is currently in phase II/III clinical trial for the treatment of breast cancer, but highly variable response has been observed among patients. We sought to discover predictive biomarker for the efficacy of BYL719 by dissecting the proliferative signaling pathway medi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yi-chao, Wang, Xiang, Chen, Yi, Chen, Si-meng, Yang, Xin-ying, Sun, Yi-ming, Geng, Mei-yu, Ding, Jian, Meng, Ling-hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381259/ https://www.ncbi.nlm.nih.gov/pubmed/28382169 http://dx.doi.org/10.7150/thno.17830

Ejemplares similares

Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors
por: Zhang, Xu, et al.
Publicado: (2023)

PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma
por: Xie, Qin, et al.
Publicado: (2021)

Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
por: Wang, Xiaofei, et al.
Publicado: (2017)

Modulation of β-Catenin Signaling by the Inhibitors of MAP Kinase, Tyrosine Kinase, and PI3-Kinase Pathways
por: Zhang, Wenwen, et al.
Publicado: (2013)

Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
por: Wang, Yu-xiang, et al.
Publicado: (2021)

Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature
por: Boonstra, Pieter A., et al.
Publicado: (2017)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
por: Chen, Chenglong, et al.
Publicado: (2022)

Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma
por: Liang, Linjun, et al.
Publicado: (2023)

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
por: Shingu, Takashi, et al.
Publicado: (2016)

miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
por: Liu, Yi-Nan, et al.
Publicado: (2020)

Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia
por: Jiang, Liling, et al.
Publicado: (2022)

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019)

Anchor-based classification and type-C inhibitors for tyrosine kinases
por: Hsu, Kai-Cheng, et al.
Publicado: (2015)

Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Wu, Peng, et al.
Publicado: (2012)

LAMC2 promotes EGFR cell membrane localization and acts as a novel biomarker for tyrosine kinase inhibitors (TKIs) sensitivity in lung cancer
por: Tong, Dongdong, et al.
Publicado: (2023)

PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review
por: Su, Shan, et al.
Publicado: (2017)

Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants
por: Bekeschus, Sander
Publicado: (2021)

Unravelling the effect of the E545K mutation on PI3Kα kinase
por: Galdadas, Ioannis, et al.
Publicado: (2020)

Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kα inhibition in breast cancer
por: Liu, Xue-Ling, et al.
Publicado: (2019)

Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia
por: Cha, Kihoon, et al.
Publicado: (2016)

Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro
por: Chiu, Hsin-Yi, et al.
Publicado: (2020)

New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound
por: Yang, Xiuyan, et al.
Publicado: (2017)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
por: Wang, Yi-Jun, et al.
Publicado: (2014)

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
por: Qu, Kai, et al.
Publicado: (2016)

The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo
por: Ma, Jingui, et al.
Publicado: (2008)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
por: Yao, Jia-Xi, et al.
Publicado: (2018)

Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines
por: Bai, Xiao-Yan, et al.
Publicado: (2016)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Differential Effects of Phosphatidylinositol 4-Kinase (PI4K) and 3-Kinase (PI3K) Inhibitors on Stomatal Responses to Environmental Signals
por: Takahashi, Sho, et al.
Publicado: (2017)

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy
por: Joshi, Avadhut D., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_vh0uo5106a3evfreim6vf7dkkn